Vice President, Science and Technology, Pharma Services, Viral Vector Service
Richard O. Snyder, Ph.D. is the Vice President for Science and Technology, Pharma Services, Viral Vector Services at Thermo Fisher Scientific, a full service CDMO providing clinical and commercial supply of viral vectors for in vivo gene therapy and ex vivo modified-cell based therapy, along with process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patients’ health. Dr. Snyder has been investigating virus biology, vector development, cGMP vector manufacturing and analytical technologies, and viral vector-mediated gene transfer for over 32 years, and was a member of teams who developed novel viral vector-based human gene therapies. Dr. Snyder was an Associate Professor of Molecular Genetics and Microbiology, and Director of Biotherapeutic Programs at the University of Florida; an Assistant Professor of Pediatrics at Harvard Medical School; and was previously employed by Cell Genesys, Somatix, Merlin, and Avigen where he was engaged in the development of gene transfer vector and vaccine technology, along with therapeutic applications. Dr. Snyder was a postdoctoral fellow at Johns Hopkins University School of Medicine, received his doctoral degree in Microbiology from The State University of New York at Stony Brook, and obtained his B.A. in Biology from Washington University in St. Louis.